DIVIS LABORATORIES
|
|
BOM : 532488     NSE : DIVISLAB     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
May 20,2022 |
Price(EOD): ₹ 4,306.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 114,340.23 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
DIVIS LABORATORIES | 2.1% | -3.3% | 4.4% |
SUN PHARMACEUTICAL INDUSTRIES | 3.4% | -0.8% | 28% |
DR REDDYS LABORATORIES | 9.2% | -1.1% | -24.4% |
CIPLA | 4.9% | -3.3% | 6.1% |
GLAND PHARMA | -1.3% | -6.3% | 1% |
PIRAMAL ENTERPRISES | 2.3% | -13.7% | 12% |
CADILA HEALTHCARE | 3.5% | -0.9% | -44% |
TORRENT PHARMACEUTICALS | 3.1% | -6.9% | -4.9% |
ALKEM LABORATORIES | 3.4% | -11.9% | -1.1% |
FUNDAMENTAL ANALYSIS OF DIVIS LABORATORIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF DIVIS LABORATORIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
57.61
P/E Calculated based on EPS of 74.75
[ Mar2021 - Consolidated Results ] 12.3
P/B Calculated based on Book Value of 350.15
[ Mar2021 - Consolidated Results ] 13.89
P/S Calculated based on Revenues of 8229.58 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
77% 77% 84% |
SHARE PRICE MOMENTUM OF DIVIS LABORATORIES
DIVIS LABORATORIES vs SENSEX
DEBT OF DIVIS LABORATORIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0 0 0.02 0.01 |
0 0 0.02 0.01 |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF DIVIS LABORATORIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF DIVIS LABORATORIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
25.45% 34.12% 36.08% 48.77% |
46.54% 58.73% 60.99% 91.71% |
QtrlyTrend |
8 | |
Latest Qtr: Dec2021 | ||
Quarterly Result Analysis → |
DIVIS LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
MFG | 4.3% | -3.1% | 9.3% |
S&P BSE QUALITY | 3.3% | -5.3% | 7.1% |
S&P BSE ALLCAP | 3.2% | -5.8% | 10.3% |
S&P BSE 500 | 3.2% | -5.6% | 9.7% |
S&P BSE LARGE MIDCAP | 3.1% | -5.2% | 9.2% |
S&P BSE LARGECAP | 3.1% | -4.7% | 9.4% |
S&P BSE 250 LARGEMIDCAP | 3.1% | -5.3% | 9.5% |
S&P BSE 200 | 3.1% | -5.2% | 9.3% |
S&P BSE CARBONEX | 3.1% | -4.8% | 9.4% |
S&P BSE SENSEX50 | 3% | -4% | 9.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY GROWTH SECTOR 15 | 3.6% | -3.2% | 3.3% |
NIFTY PHARMA | 3.5% | -3.4% | -5.7% |
NIFTY500 MULTICAP 50:25:25 | 3.4% | -6.8% | 11% |
NIFTY 500 | 3.1% | -5.7% | 9.7% |
NIFTY 100 | 3.1% | -4.9% | 8.9% |
NIFTY 50 | 3.1% | -4.1% | 9% |
NIFTY50 EQUAL WEIGHT | 3.1% | -4.8% | 9.7% |
NIFTY HEALTHCARE | 3% | -6.2% | -3.4% |
NIFTY 200 | 3% | -5.3% | 9.3% |
NIFTY LARGE MIDCAP 250 | 3% | -6% | 10.5% |
You may also like the below Video Courses
FAQ about DIVIS LABORATORIES
Is DIVIS LABORATORIES good for long term investment?
As on May 20,2022, the Fundamentals of DIVIS LABORATORIES look Strong and hence it may be good for long term investment! See Financial Performance of DIVIS LABORATORIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is DIVIS LABORATORIES UnderValued or OverValued?
As on May 20,2022, DIVIS LABORATORIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of DIVIS LABORATORIES ?
As on May 20,2022, the Intrinsic Value of DIVIS LABORATORIES is Rs. 2,434.88 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 2,437.80
Fair Value [Median EV / Sales Model] : Rs. 2,434.88
Fair Value [Median Price / Sales Model] : Rs. 2,336.58
Median Fair Value of DIVIS LABORATORIES : Rs. 2,434.88
Is DIVIS LABORATORIES trading at a Premium or Discount?
As on May 20,2022, DIVIS LABORATORIES is trading at a Premium of 77% based on the estimates of Median Intrinsic Value!
Quarterly Results of SUN PHARMACEUTICAL INDUSTRIES LTD Quarterly Results of DR REDDYS LABORATORIES LTD Quarterly Results of CIPLA LTD Quarterly Results of GLAND PHARMA LTD |
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
Market Cap of SUN PHARMACEUTICAL INDUSTRIES LTD Market Cap of DR REDDYS LABORATORIES LTD Market Cap of CIPLA LTD Market Cap of GLAND PHARMA LTD |
